トップ›研究者一覧›河野豊

研究者を探す

研究者にアプローチする
更新情報を通知する

河野豊

徳島大学

プロフィール
教育活動
研究活動
社会活動
リサーチマップ・
Jグローバル
KAKEN
注目研究

研究者総覧で最新データを確認する

2024年11月22日更新

職名: 特任教授
電話: 0886339235
電子メール: ykawano@tokushima-u.ac.jp
学歴: 研究者総覧に該当データはありませんでした。
学位: ヒト不死化ストローマ細胞を用いた臍帯血造血幹細胞の増幅に関する研究 (札幌医科大学) (2003年3月)
職歴・経歴: 2022/4: 徳島大学特任准教授, 大学院医歯薬学研究部 (-2024.10.)
2024/11: 徳島大学特任教授, 大学院医歯薬学研究部

専門分野・研究分野: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2024年11月22日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。
担当経験のある授業科目: 研究者総覧に該当データはありませんでした。
指導経験: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2024年11月22日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。

研究テーマ: 研究者総覧に該当データはありませんでした。

著書

研究者総覧に該当データはありませんでした。

論文

Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Aasahiro Morishita, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice.,
JGH Open, Vol.8, No.10, e70033, 2024.

(出版サイトへのリンク): ● Publication site (DOI): 10.1002/jgh3.70033.
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39371045; ● Search Scopus @ Elsevier (PMID): 39371045; ● Search Scopus @ Elsevier (DOI): 10.1002/jgh3.70033.

(DOI: 10.1002/jgh3.70033., PubMed: 39371045) Kazuyoshi Noda, Yasushi Sato, Yasuyuki Okada, Kensei Nishida, Yutaka Kawano, Toshihito Tanahashi, Masahiro Bando, Koichi Okamoto, Masanori Takehara, Masahiro Sogabe, Hiroshi Miyamoto, Kei Daizumoto, Hiro-omi Kanayama and Tetsuji Takayama :
Exosomal miR-199a-3p Secreted From Cancer-Associated Adipocytes Promotes Pancreatic Cancer Progression.,
Cancer Medicine, Vol.13, No.20, e70265, 2024.

(出版サイトへのリンク): ● Publication site (DOI): 10.1002/cam4.70265.
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39431622; ● Search Scopus @ Elsevier (PMID): 39431622; ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.70265.

(DOI: 10.1002/cam4.70265., PubMed: 39431622) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, Ryo Shinomiya, Takanori Miyake, Tomoyuki Kawaguchi, Reiko Yokoyama, Kaizo Kagemoto, Yoshifumi Kida, Yasuyuki Okada, Tetsu Tomonari, Yutaka Kawano, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease.,
Alimentary Pharmacology & Therapeutics, Vol.Online ahead of print, 2024.

(出版サイトへのリンク): ● Publication site (DOI): 10.1111/apt.18280
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39310953; ● Search Scopus @ Elsevier (PMID): 39310953; ● Search Scopus @ Elsevier (DOI): 10.1111/apt.18280

(DOI: 10.1111/apt.18280, PubMed: 39310953) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.,
Journal of Gastroenterology and Hepatology, Vol.39, No.6, 1107-1114, 2024.

(要約): Although erosive esophagitis (EE) is associated with fatty liver and metabolic dysregulation, the association between EE and metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Thus, this study aimed to investigate the longitudinal association between MASLD and EE. We included 1578 patients without EE at baseline who underwent more than two health checkups over 2 years. Generalized estimation equations were used to analyze associations between MASLD and EE according to repeated measures at baseline and most recent stages. EE development rates in men and women were 14.5% and 7.2%, respectively. After adjusting for lifestyle habits, the odds ratios of MASLD for EE development in men and women were 1.907 (95% confidence interval [CI]: 1.289-2.832, P < 0.005) and 1.483 (95% CI: 0.783-2.811, P = 0.227), respectively. In the subgroup analysis, after adjusting for lifestyle habits, among men and women aged 50 years with more than three MASLD components, the odds ratios for EE development were 2.408 (95% CI: 1.505-3.855, P < 0.001) and 2.148 (95% CI: 1.093-4.221, P < 0.05), respectively. After adjusting for various factors, the significant risk factors for EE development were different between men and women. The influence of MASLD and other factors on EE development differed by sex and age. Particularly, patients aged 50 years with MASLD and with an increased number of MASLD components should be considered at increased risk for EE.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.16530
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38419514; ● Search Scopus @ Elsevier (PMID): 38419514; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16530

(DOI: 10.1111/jgh.16530, PubMed: 38419514) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, shota Fujimoto, Tomoyuki Kawaguchi, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Yutaka Kawano, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Impact of alcohol consumption on metabolic dysfunction-associated fatty liver disease development and remission: A longitudinal cohort study.,
European Journal of Clinical Investigation, Vol.Online ahead of print., e14221, 2024.

(要約): The influence of alcohol intake on metabolic dysfunction-associated fatty liver disease (MAFLD) development and remission remains unclear; thus, we aimed to investigate their longitudinal associations. This observational cohort study included 6349 patients who underwent more than two health check-ups over >2 years between April 2013 and March 2021. Generalized estimation equations were used to analyse the longitudinal associations between changes in alcohol intake and MAFLD according to repeated measures at baseline and the most recent stage. The MAFLD development and remission rates were 20.4 and 5.1 and 9.1 and 4.7% in men and women, respectively. Although alcohol consumption was not a significant factor for MAFLD development, consuming 0.1-69.9 g/week (odds ratio [OR]: 0.672, 95% confidence interval [CI]: 0.469-0.964, p < .05) and ≥280 g/week were significant factors for MAFLD development in males (OR: 1.796, 95% CI: 1.009-3.196, p < .05) and females (OR: 16.74, 95% CI: 3.877-72.24, p < .001). Regardless of quantity and frequency, alcohol consumption was not a significant factor for MAFLD remission. Several noninvasive liver fibrosis scores were significantly associated with alcohol intake quantity and frequency in males with MAFLD development and remission (p < .05). The nonalcoholic fatty liver disease fibrosis score differed significantly between males with and without reduced alcohol intake (p < .05) who showed MAFLD remission. Although the influence of alcohol intake on MAFLD development and remission differed, alcohol consumption was not beneficial for MAFLD remission in either sex. Alcohol intake reduction or cessation is recommended to prevent liver fibrosis, even in those who achieve MAFLD remission.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/eci.14221
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38634705; ● Search Scopus @ Elsevier (PMID): 38634705; ● Search Scopus @ Elsevier (DOI): 10.1111/eci.14221

(DOI: 10.1111/eci.14221, PubMed: 38634705) Ryo Shinomiya, Yasushi Sato, Takanori Yoshimoto, Tomoyuki Kawaguchi, Akihiro Hirao, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
A case of treatmentresistant advanced gastric cancer with FGFR2gene alteration successfully treated with pemigatinib.,
International Cancer Conference Journal, Vol.13, 240-244, 2024.

(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s13691-024-00669-3
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.1007/s13691-024-00669-3

(DOI: 10.1007/s13691-024-00669-3) Yutaka Kawano, Maki Tanaka, Yasushi Sato, Shigekazu Sugino, Jun Suzuki, Masaki Fujishima, Eri Okumura, Hideo Takekoshi, Osamu Uehara, Shintaro Sugita, Yoshihiro Abiko, Tetsu Tomonari, Hironori Tanaka, Hidekatsu Takeda and Tetsuji Takayama :
Acanthopanax senticosus ameliorates steatohepatitis through HNF4 alpha pathway activation in mice.,
Scientific Reports, Vol.14, No.1, 110, 2024.

(要約): Non-alcoholic fatty liver disease is a common liver disease worldwide, and is associated with dysregulation of lipid metabolism, leading to inflammation and fibrosis. Acanthopanax senticosus Harms (ASH) is widely used in traditional medicine as an adaptogen food. We examined the effect of ASH on steatohepatitis using a high-fat diet mouse model. Mice were fed a choline-deficient, L-amino acid-defined, high-fat diet with ASH extract (ASHE). After 6 weeks, liver RNA transcriptome sequencing (RNA-Seq) was performed, followed by Ingenuity Pathway Analysis (IPA). Our findings revealed that mice fed a high-fat diet with 5% ASHE exhibited significantly reduced liver steatosis. These mice also demonstrated alleviated inflammation and reduced fibrosis in the liver. IPA of RNA-Seq indicated that hepatocyte nuclear factor 4 alpha (HNF4 alpha), a transcription factor, was the activated upstream regulator (P-value 0.00155, z score = 2.413) in the liver of ASHE-fed mice. Adenosine triphosphate binding cassette transporter 8 and carboxylesterase 2, downstream targets of HNF4 alpha pathway, were upregulated. Finally, ASHE-treated HepG2 cells exposed to palmitate exhibited significantly decreased lipid droplet contents. Our study provides that ASHE can activate HNF4 alpha pathway and promote fat secretion from hepatocytes, thereby serving as a prophylactic treatment for steatohepatitis in mice.
(キーワード): Animals / Mice / Hepatocyte Nuclear Factor 4 / Eleutherococcus / Liver / Non-alcoholic Fatty Liver Disease / Inflammation / Disease Models, Animal / Fibrosis / Mice, Inbred C57BL / Diet, High-Fat
(徳島大学機関リポジトリ): ● Metadata: 119444
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/s41598-023-50625-z
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38167633; ● Search Scopus @ Elsevier (PMID): 38167633; ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-50625-z

(徳島大学機関リポジトリ: 119444, DOI: 10.1038/s41598-023-50625-z, PubMed: 38167633) Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Asahiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Tsutomu Masaki and Tetsuji Takayama :
Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.,
Cancers, Vol.15, No.21, 5221, 2023.

(要約): <jats:p>This retrospective multicenter study analyzed 244 patients with unresectable hepatocellular carcinoma treated with lenvatinib (LEN) and atezolizumab + bevacizumab (Atezo + Bev) to examine the characteristics, treatment courses, and prognoses. The cases of patients who could achieve HCC downstaging from Barcelona Clinic Liver Cancer (BCLC) stage B or C to A or zero indicated the need for conversion therapy. The patients' prognoses with and without conversion therapy were compared. Of the 244 patients, 12 (4.9%) underwent conversion therapy, six out of 131 (4.6%) were treated with LEN, and six out of 113 (5.3%) were treated with Atezo + Bev. Eleven patients (91.7%) with a modified albumin bilirubin (mALBI) grade 1 or 2a and BCLC-B stage showed significantly higher rates of transition during conversion therapy (p < 0.05). The patients undergoing conversion therapy had a significantly longer median overall survival rate than those receiving chemotherapy alone (1208 [1064–NA] vs. 569 [466–704] days, p < 0.01). A comparison of the patients who achieved a partial response with and without conversion was evaluated using propensity score matching to reduce the confounding factors, showing a significant survival benefit in the conversion group (1208 [1064–NA] vs. 665 days, p < 0.01). Among the patients with u-HCC who were treated with LEN and Atezo + Bev, those with mALBI 1 + 2a and BCLC-B were likely to achieve conversion therapy with downstaging.</jats:p>
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/cancers15215221
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1360580235903920000; ● Summary page in Scopus @ Elsevier: 2-s2.0-85176601973

(DOI: 10.3390/cancers15215221, CiNii: 1360580235903920000, Elsevier: Scopus) Reiko Yokoyama, Yasushi Sato, Fumika Nakamura, Kaizo Kagemoto, Yasuhiro Mitsui, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.,
Clinical Journal of Gastroenterology, Vol.Online ahead of print., 2023.

(要約): Anorectal melanoma (AM) is a rare subtype of mucosal melanoma with a poor prognosis. Given its rarity compared to its cutaneous counterpart, the benefits and side effects of immune checkpoint inhibitor (ICI) therapy and the relationship between side effects and prognosis remain unclear. Herein, we describe the clinical presentation of five patients with AM treated with ICI as well as their relationship to the treatment course and the development of immune-related adverse events (irAEs). Three patients received sequential or concurrent administrations of nivolumab and ipilimumab, one received nivolumab alone, and one received ipilimumab alone. The response rate (RR) and disease control rate (DCR) were 40% and 80%, respectively. Pituitary and hepatic dysfunctions were the most common irAEs observed (40% each), followed by thyroid, diarrhea, and renal dysfunctions (20% each). The RR was 67% in patients with irAEs while no response was observed in patients without irAEs. DCR was 100% and 50% in patients with and without irAEs, respectively. Overall survival was 34 months in irAE and 8.75 months in non-irAE cases, with a longer survival trend in irAE cases. ICI therapy was effective and well-tolerated by AM patients, with potentially better outcomes for those who experienced irAEs compared to those who did not.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-023-01849-z
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37632658; ● Summary page in Scopus @ Elsevier: 2-s2.0-85169147432

(DOI: 10.1007/s12328-023-01849-z, PubMed: 37632658, Elsevier: Scopus) Yasushi Sato, Koichi Okamoto, Yutaka Kawano, Akinari kasai, Tomoyuki Kawaguchi, Tamotsu Sagawa, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.,
Journal of Clinical Medicine, Vol.12, 4646, 2023.

(出版サイトへのリンク): ● Publication site (DOI): 10.3390/jcm12144646
(文献検索サイトへのリンク): ● Summary page in Scopus @ Elsevier: 2-s2.0-85166316472

(DOI: 10.3390/jcm12144646, Elsevier: Scopus) Tamotsu Sagawa, Yasushi Sato, Hiroyuki Nagashimia, Kohichi Takada, Mamoru Takahashi, Masahiro Hiarakawa, Kyoko Hamaguchi, Fumito Tamura, Koshi Fujikawa, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.,
Frontiers in Immunology, Vol.14, 1203621, 2023.

(要約): Immune checkpoint inhibitors (ICIs) are the standard treatment for metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). Among immune-related adverse events (irAEs), drug-induced sarcoidosis-like reactions (DISR) are often difficult to differentiate from cancer progression. This is a case of a woman in her mid-60s, with mCRC (RAS wild/BRAF mutant/MSI-H) and abdominal lymph node metastasis, treated with four courses of ipilimumab + nivolumab every 3 weeks, followed by nivolumab every 2 weeks as third-line treatment. After treatment, the original lymph node metastases shrank, but hilar/mediastinal lymph nodes appeared. Endoscopic ultrasound-guided fine-needle aspiration of these lymph nodes revealed multiple epithelioid granulomas without necrosis, indicating a sarcoidosis-like reaction. Fluorodeoxyglucose-positron emission tomography scan showed abnormal subcutaneous accumulation in bilateral forearms and bilateral knee joints. Biopsy of the cutaneous lesions was also performed, which revealed epithelioid granulomas. As the patient had no symptoms in other organs, no specific therapeutic intervention was administered. After the discontinuation of immunotherapy, the sarcoidosis-like reaction regressed without cancer relapse. Clinicians should be aware of the possibility of DISR as an irAE during the ICI treatment of mCRC. In suspected cases of DISR following ICI therapy, it is important to differentiate between cancer progression and DISR through histological diagnosis for the subsequent strategy, as radiological and serological findings are not definitive.
(キーワード): Humans / Female / Nivolumab / Immune Checkpoint Inhibitors / Neoplasm Recurrence, Local / Sarcoidosis / Colonic Neoplasms / Rectal Neoplasms / Granuloma / Lymphatic Metastasis
(出版サイトへのリンク): ● Publication site (DOI): 10.3389/fimmu.2023.1203621
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37492584; ● Summary page in Scopus @ Elsevier: 2-s2.0-85165588753

(DOI: 10.3389/fimmu.2023.1203621, PubMed: 37492584, Elsevier: Scopus) Tamotsu Sagawa, Yasushi Sato, Masahiro Hirakawa, Kyoko Hamguchi, Fumito Tamura, Hiroyuki Nagashima, Koshi Fujikawa, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer.,
Frontiers in Oncology, Vol.13, 1203296, 2023.

(要約): Treatment with anti-EGFR antibody has been shown to prolong survival in patients with RAS wild-type metastatic colorectal cancer (mCRC). However, even patients who initially respond to anti-EGFR antibody therapy, almost without exception, develop resistance to the therapy and then fail to respond. Secondary mutations in the mitogen-activated protein (MAPK) signaling pathway (mainly in NRAS and BRAF) have been implicated in anti-EGFR resistance. However, the process by which resistant clones develop during therapy has not been elucidated, and considerable intrapatient and interpatient heterogeneity exists. Circulating tumor DNA (ctDNA) testing has recently allowed the noninvasive detection of heterogeneous molecular alterations that underlie the evolution of resistance to anti-EGFR. In this report, we describe our observation of genomic alterations in and in a patient with acquired resistance to anti-EGFR antibody drugs by tracking clonal evolution using serial ctDNA anaylsis. A 54-year-old woman was initially diagnosed with sigmoid colon cancer with multiple liver metastases. After receiving first-line mFOLFOX + cetuximab, second-line FOLFIRI + ramucirumab, third-line trifluridine/tipiracil + bevacizumab, fourth-line regorafenib, and fifth-line CAPOX + bevacizumab, she was rechallenged with CPT-11 + cetuximab. The best response to anti-EGFR rechallenge therapy was a partial response. in the ctDNA was assessed during treatment. The status changed from wild type to mutant type, back to wild type, and again to mutant type ( codon 61) during the course of treatment. In this report, tracking of ctDNA allowed us to describe clonal evolution in a case in which we observed genomic alterations in and in a patient who acquired resistance to anti-EGFR antibody drugs during treatment. It is reasonable to consider repeat molecular interrogation during progression in patients with mCRC by using ctDNA analysis, which could help to identify patients who may benefit from a rechallenge strategy.
(出版サイトへのリンク): ● Publication site (DOI): 10.3389/fonc.2023.1203296
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37434969; ● Summary page in Scopus @ Elsevier: 2-s2.0-85164679900

(DOI: 10.3389/fonc.2023.1203296, PubMed: 37434969, Elsevier: Scopus) Osamu Uehara, Norihiro Nakamoto, Daichi Hiraki, Durga Paudel, Nodoka Sugiyama, Tetsuro Morikawa, Koki Yoshida, Yutaka Kawano, Tsuyoshi Shimo, Yasushi Furuichi, Hiroko Miura and Yoshihiro Abiko :
Effects of prolonged stimulation with heated tobacco products (Ploom TECH+) on gingival epithelial cells,
Journal of Periodontal Research, Vol.58, No.3, 553-563, 2023.

(要約): tobacco capsules and water were mixed and heated; the supernatant subsequently collected was the heated tobacco product (HTP; control: HTP not added). Normal human gingival epithelial progenitors were cultured alternately with or without HTP for a total of 1 month. Subsequently, RNA, DNA, and proteins were isolated from these samples and comprehensively analyzed using RNA sequencing (RNA-seq), reduced representation bisulfite sequencing (RRBS), and western blotting, respectively.
(キーワード): Humans / Tobacco Products / Tobacco / Risk Factors / Hot Temperature / Epithelial Cells
(徳島大学機関リポジトリ): ● Metadata: 118466
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jre.13123
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36974375; ● Search Scopus @ Elsevier (PMID): 36974375; ● Search Scopus @ Elsevier (DOI): 10.1111/jre.13123

(徳島大学機関リポジトリ: 118466, DOI: 10.1111/jre.13123, PubMed: 36974375) Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama :
A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.,
Clinical Journal of Gastroenterology, Vol.16, No.3, 438-443, 2023.

(要約): The efficacy of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN-TACE) has been reported, but its effect on unresectable hepatocellular carcinoma (HCC) refractory to LEN therapy has not been demonstrated. We report a case of HCC refractory to multiple molecular-targeted agents (MTA) treatments, including LEN, that was successfully treated with LEN-TACE. A 59-year-old man was referred to our department with multiple HCCs and a background of hepatitis B virus infection. TACE was the initial treatment. However, he was determined to be TACE-refractory, and multitargeted therapy was initiated. LEN was started at 12 mg/day but resulted in progressive disease (PD) after 13 months of the administration. The response to second-line sorafenib was PD after 2 months. Third-line therapy with atezolizumab + bevacizumab was stopped after one course because of an immune-related adverse event (i.e., dermatitis). The response to fourth-line regorafenib was PD at 2 months, and the response to fifth-line cabozantinib was PD after 6 months. The efficacy of LEN-TACE was recently reported; therefore, we decided to attempt LEN-TACE therapy as a salvage line. After obtaining the patient's consent to repeat LEN and TACE, treatment was initiated. The tumor markers levels markedly reduced after LEN-TACE therapy. After three additional TACE treatments with continued LEN administration, the tumor marker levels normalized, and complete response was determined based on RECIST guidelines. LEN-TACE therapy may effectively treat unresectable advanced HCC in the LEN-rechallenge setting and may be a treatment option as a last-line therapeutic option.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-023-01777-y
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36856957; ● Search Scopus @ Elsevier (PMID): 36856957; ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-023-01777-y

(DOI: 10.1007/s12328-023-01777-y, PubMed: 36856957) Tetsu Tomonari, Joji Tani, Chikara Ogawa, Akihiro Deguchi, Tomonori Senoh, Akio Moriya, Hiroshi Shibata, Hiroshi Fukuno, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Akihiro Morishita, Koichi Takaguchi, Hiroshi Miyamoto, Yasushi Sato, Tsutomu Masaki and Tetsuji Takayama :
Multicenter retrospective study of Initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.,
Hepatology Research, Vol.53, No.2, 172-178, 2023.

(要約): Cabozantinib (CAB), a multiple kinase inhibitor, has been approved for use in patients with previously treated unresectable hepatocellular carcinoma (uHCC). However, real-world clinical data are lacking, particularly clinical data regarding dose modifications of CAB. We analyzed the clinical outcomes of CAB in uHCC and compared treatment outcomes between the full- and reduced-dose groups. This multicenter, observational study included patients with uHCC who were treated with CAB from March 2021 to April 2022. Patient characteristics, efficacy, and safety were compared between the full- and reduced-dose groups. Twenty-six patients from eight institutes were analyzed. Cabozantinib was administered as a third-line or later treatment in 25 (96.2%) patients and postimmunotherapy in 21 (80.5%) patients. There were 15 patients in the full-dose group (60 mg CAB) and 11 in the reduced-dose group (40 or 20 mg CAB). The objective response rate (ORR) and disease control rate (DCR) were not significantly different between the two groups. The ORR was 6.7% for the full-dose group and 9.1% for the reduced-dose group, and the DCR was 53.4% and 81.8%, respectively. Progression-free survival analysis showed no significant differences between the two groups. The incidence of decreased appetite, fatigue, and diarrhea, and the rate of discontinuation and dose reduction, was significantly higher in the full-dose group. Our study suggests that the efficacy and safety of CAB in real-world clinical practice are comparable to those of the phase III trial (CELESTIAL), and that dose reduction of CAB may be a safer treatment option.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/hepr.13845
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36214071; ● Search Scopus @ Elsevier (PMID): 36214071; ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13845

(DOI: 10.1111/hepr.13845, PubMed: 36214071) Yasushi Sato, Yasuyuki Okada, Yasuteru Fujino, Tomoyuki Kawaguchi, Yoshifumi Kida, Yasuhiro Mitsui, Hironori Tanaka, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Masahiro Sogabe and Tetsuji Takayama :
Clinical Outcomes of Comprehensive Genomic Profiling Tests for Gastrointestinal Cancers: Experience from Tokushima University Hospital.,
The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 154-159, 2023.

(要約): In Japan, cancer genome profiling (CGP) for cancer patients without standard treatment has been covered by public insurance since June 2019. This study analyzed data of 122 patients with gastrointestinal tumors who underwent CGP to clarify cancer genome medicine's current status and possible problems at the Tokushima University Hospital. The major types of cancer included pancreatic (n=30), colorectal (n=25), biliary tract (n=15), gastric (n=11), and hepatocellular carcinoma (n=8). CGP tests included F1CDx in 70 patients (57%), F1LCDx in 36 (30%), TSO500 in 14 (11%), and NCC Oncopanel in 2 (2%). Actionable gene alterations were identified in 72 patients (59%), but only 5 patients (4%) were treated for pancreatic (n=1), colorectal (n=3), and small bowel cancers (n=1). The main reasons for not receiving genotype-matched therapy included the lack of appropriate drugs or clinical trials that matched the actionable gene alterations (n=40) and the inability to participate in clinical trials (n=10). There is still not a sufficient number of patients receiving genotype-matched treatment for gastrointestinal cancers. To promote cancer genome medicine in regional areas, attempts to improve access to genotype-matched therapies are required, as well as to promote the development of new molecular-targeted drugs and clinical trials for these drugs. J. Med. Invest. 70 : 154-159, February, 2023.
(キーワード): Humans / Gastrointestinal Neoplasms / Neoplasms / Colorectal Neoplasms / Genomics / Hospitals / Japan
(徳島大学機関リポジトリ): ● Metadata: 118346
(出版サイトへのリンク): ● Publication site (DOI): 10.2152/jmi.70.154
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164713; ● Search Scopus @ Elsevier (PMID): 37164713; ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.154

(徳島大学機関リポジトリ: 118346, DOI: 10.2152/jmi.70.154, PubMed: 37164713) 河野豊, 吉田純一, 原田文也, 植原治, 安彦善裕, 永易裕樹, 舞田建夫, 川上智史, 江口有一郎 :
ヒト型ロボットPepperを用いた肝炎ウイルス検査受検推奨の効果検証,
肝臓, Vol.63, No.8, 388-391, 2022年.

(出版サイトへのリンク): ● Publication site (DOI): 10.2957/kanzo.63.388
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1390293025962862080; ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.63.388

(DOI: 10.2957/kanzo.63.388, CiNii: 1390293025962862080) Yutaka Kawano :
Alterations in the oral microbiome of individuals with a healthy oral environment following COVID-19 vaccination,
BMC Oral Health, Vol.22, No.1, 2022.

(要約): Several reports suggest that the microbiome of the digestive system affects vaccine efficacy and that the severity of coronavirus disease (COVID-19) is associated with decreased diversity of the oral and/or intestinal microbiome. The present study examined the effects of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine on the oral microbiome. Forty healthy Japanese oral healthcare personnel were recruited, and unstimulated saliva was collected before vaccination, after the 1st vaccination, and after the 2nd vaccination. Genomic DNA was extracted from saliva samples, and PCR amplicons of the 16S rRNA gene were analyzed using next-generation sequencing. Microbial diversity and composition were analyzed using Quantitative Insights into Microbial Ecology 2. In addition, alterations in microbial function were assessed using PICRUSt2. SARS-CoV-2 mRNA vaccination significantly increased oral bacterial diversity and significantly decreased the proportion of the genus Bacteroides. The SARS-CoV-2 mRNA vaccine alters the oral microbiome; accordingly, vaccination might have beneficial effects on oral health.
(キーワード): 16S rRNA / COVID-19 / Healthy oral environment / Oral microbiome / ワクチン (vaccine)
(出版サイトへのリンク): ● Publication site (DOI): 10.1186/s12903-022-02093-6
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35241064; ● Summary page in Scopus @ Elsevier: 2-s2.0-85125689547

(DOI: 10.1186/s12903-022-02093-6, PubMed: 35241064, Elsevier: Scopus)

MISC

河野豊 :
食べ過ぎだけではない肥満の理由,
生物工学会誌, Vol.101, No.1, 33, 2023年.

(出版サイトへのリンク): ● Publication site (DOI): 10.34565/seibutsukogaku.101.1_33
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1390013408148989824; ● Search Scopus @ Elsevier (DOI): 10.34565/seibutsukogaku.101.1_33

(DOI: 10.34565/seibutsukogaku.101.1_33, CiNii: 1390013408148989824)

総説・解説

Yasushi Sato, Koichi Okamoto, Yoshifumi Kida, Yasuhiro Mitsui, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Overview of Chemotherapy for Gastric Cancer.,
Journal of Clinical Medicine, Vol.12, No.4, 1336, Feb. 2023.

(要約): Gastric cancer (GC) is one of the most clinically challenging cancers worldwide. Over the past few years, new molecular-targeted agents and immunotherapy have markedly improved GC prognosis. Human epidermal growth factor receptor 2 (HER2) expression is a key biomarker in first-line chemotherapy for unresectable advanced GC. Further, the addition of trastuzumab to cytotoxic chemotherapy has extended the overall survival of patients with HER2-positive advanced GC. In HER2-negative GC, the combination of nivolumab, an immune checkpoint inhibitor, and a cytotoxic agent has been demonstrated to prolong the overall survival of GC patients. Ramucirumab and trifluridine/tipiracil, which are second- and third-line treatments for GC, and trastuzumab deruxtecan, an antibody-drug conjugate for HER2-positive GC, have been introduced in clinics. New promising molecular-targeted agents are also being developed, and combination therapy comprising immunotherapy and molecular-targeted agents is expected. As the number of available drugs increases, it is important to understand the target biomarkers and drug characteristics and select the optimal therapy for each patient. For resectable disease, differences in the extent of standard lymphadenectomy between Eastern and Western countries have led to different standard treatments: perioperative (neoadjuvant) and adjuvant therapy. This review aimed to summarize recent advances in chemotherapy for advanced GC.
(徳島大学機関リポジトリ): ● Metadata: 118894
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/jcm12041336
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36835872; ● Search Scopus @ Elsevier (PMID): 36835872; ● Search Scopus @ Elsevier (DOI): 10.3390/jcm12041336

(徳島大学機関リポジトリ: 118894, DOI: 10.3390/jcm12041336, PubMed: 36835872)

講演・発表

Hironori Tanaka, Tetsu Tomonari, Ryo Shinomiya, Mai Yonezawa, Yutaka Kawano and Tetsuji Takayama :
Usefulness of shear wave elastography for evaluation of HCC recurrence after ablation.,
APASL2024, Kyoto, Mar. 2024. Yutaka Kawano, Maki Tanaka, Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takeshi Mitsuhashi and Tetsuji Takayama :
Activation of HNF4α pathway by treatment with botanical plant, Acanthopanax Senticosus, ameliorates steatohepatitis in high-fat fed mice model.,
AASLD2023, Boston, Nov. 2023. Yasushi Sato, Kazuyoshi Noda, Yasuyuki Okada, Kensei Nishida, Yutaka Kawano, Toshihito Tanahashi, Masanori Takehara, Yasuteru Fujino, Koichi Okamoto, Hiroshi Miyamoto and Tetsuji Takayama :
Exosomal miR-199a-3p secreted from cancer-associated adipocytes promote pancreatic cancer progression.,
DDW2023, Chicago, May 2023. Yutaka Kawano, Maki Tanaka, Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takeshi Mitsuhashi and Tetsuji Takayama :
Activation of HNF4α pathway by treatment with botanical plant, Acanthopanax senticosus, ameliorates steatohepatitis in high-fat fed mice model.,
DDW2023, Chicago, May 2023. 河野豊, 福田伊津子, 田中真樹, 佐藤康史, 高山哲治 :
KUHIMMiBを用いたエゾウコギの腸内細菌叢への影響.,
クロレラ・機能性植物研究会第6回研究集会, 2024年9月. 上田浩之, 田中宏典, 米田健一, 米澤真衣, 友成哲, 河野豊, 高山哲治 :
<パネルディスカッション>食道静脈瘤の評価におけるMR Elastographyの有用性.,
第31回日本門脈圧亢進症学会総会, 2024年9月. 三橋威志, 河野豊, 佐藤康史, 友成哲, 田中宏典, 米澤真衣, 高山哲治 :
フィトケミカル食品エゾウコギを用いたMAFLD/MASH に対する有効性の基礎検討.,
第31回日本がん予防学会総会(日本がん予防学会学術大会2024徳島), 2024年9月. 友成哲, 谷丈二, 田中宏典, 河野豊, 森下朝洋, 正木勉, 高山哲治 :
切除不能肝細胞癌に対する後治療を見据えたデュルバルマブ+トレメリムマブ併用療法の治療成績.,
第30回日本肝がん分子標的治療研究会, 2024年7月. 田中宏典, 友成哲, 河野豊, 高山哲治 :
肝細胞癌に対する定位放射線療法の有効性.,
第60回肝癌研究会, 2024年7月. 河野豊, 四柳宏, 江口有一郎, 湯本浩通, 舞田健夫, 高山哲治 :
<特別企画>歯科領域における肝炎対策の実態調査と課題解決について.,
第60回日本肝臓学会総会, 2024年6月. 田中宏典, 米澤真衣, 友成哲, 河野豊, 高山哲治 :
Ultrasound-guided attenuation parameter(UGAP)を用いた肝脂肪化の評価.,
日本超音波医学会第97回学術集会, 2024年6月. 田中宏典, 友成哲, 米澤真衣, 河野豊, 高山哲治 :
<ワークショップ>食道静脈瘤の評価におけるMR Elastographyの有用性.,
第110回日本消化器病学会総会, 2024年5月. 樫原孝典, 三宅孝典, 岡本耕一, 河野豊, 六車直樹, 佐藤康史, 高山哲治 :
<ワークショップ>蛍光標識フラグメント化抗c-KIT抗体を用いた消化管間質腫瘍(GIST)の蛍光内視鏡診断の試み.,
第110回日本消化器病学会総会, 2024年5月. 米澤真衣, 田中宏典, 友成哲, 河野豊, 高山哲治 :
<シンポジウム>肝脂肪化の評価におけるultrasound-guided attenuation parameter(UGAP)の有用性.,
第110回日本消化器病学会総会, 2024年5月. 河野豊, 友成哲, 佐藤康史, 高山哲治 :
MAFLD/MASHマウスモデルを用いたフィトケミカル含有食品エゾウコギの基礎検討.,
第42回Cytoprotection研究会, 2024年3月. 福家慧, 佐藤康史, 岡田泰行, 岡本耕一, 河野豊, 宮本弘志, 高山哲治, 影本開三, 喜田慶史 :
UBR4 は EGFR の内在化を制御することで，大腸癌患者における抗 EGFR 抗体の新規バイオマーカーとなる.,
第21回日本臨床腫瘍学会学術集会, 2024年2月. 藤本将太, 樫原孝典, 三宅孝典, 岡本耕一, 河野豊, 宮本弘志, 曽我部正弘, 佐藤康史, 高山哲治 :
抗c-KIT抗体フラグメントと近赤外蛍光内視鏡を用いた水分子イメージングおよび光治療によるGISTの新規診断治療法の開発.,
第20回日本消化管学会総会学術集会, 2024年2月. 友成哲, 谷丈二, 田中宏典, 河野豊, 森下朝洋, 正木勉, 高山哲治 :
切除不能肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の初期治療成績.,
第29回日本肝がん分子標的治療研究会, 2024年1月. 横山怜子, 佐藤康史, 中村文香, 川口智之, 影本開三, 喜田慶史, 三井康裕, 藤野泰輝, 岡本耕一, 河野豊, 宮本弘志, 高山哲治 :
直腸悪性黒色腫に対する免疫チェックポイント阻害剤の効果予測因子としての irAE の意義.,
第 61 回日本癌治療学会学術集会, 2023年10月. 河野豊, 渡邉奈々恵, 西山正彦, 小野薫, 佐藤康史, 照井健, 日下部俊郎, 友成哲, 田中宏典, 高山哲治 :
がん関連疲労に対するエゾウコギ含有食品の実行可能性試験.,
第 61 回日本癌治療学会学術集会, 2023年10月. 河野豊, 田中真樹, 藤島雅基, 奥村衣梨, 竹腰英夫, 武田秀勝, 佐藤康史, 高山哲治 :
脂肪肝モデルマウスを用いた，エゾウコギによる治療応用に向けての基礎研究第2報.,
クロレラ・機能性植物研究会第5回研究集会, 2023年10月. 友成哲, 田中宏典, 河野豊, 佐藤康史, 高山哲治 :
デュルバルマブ+トレメリムマブ併用療法を見据えた肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療戦略.,
第28回日本肝がん分子標的治療研究会, 2023年6月. 友成哲, 田中宏典, 谷口達哉, 河野豊, 宮本弘志, 高山哲治 :
悪性肝腫瘍に対するEmprint Ablation Systemの治療成績.,
日本超音波医学会第96回学術集会, 2023年5月. Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Tsutomu Masaki and Tetsuji Takayama :
アテゾリズマブ+ベバシズマブ，レンバチニブを用いた切除不能肝細胞癌に対する根治的Conversion therapyの治療成績.,
第20回日本臨床腫瘍学会学術集会, Mar. 2023. 友成哲, 田中宏典, 谷口達哉, 河野豊, 高山哲治 :
切除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法後のレンバチニブ及び根底的Conversion治療の有効性.,
第27回日本肝がん分子標的治療研究会, 2023年1月. 河野豊 :
非アルコール性脂肪肝疾患(NAFLD)に対するエソウコギエキスの基礎的検討,
肝臓, Vol.63, A312, 2022年4月.

研究会・報告書: 河野豊, 渡邉奈々恵, 田中真樹, 藤島雅基, 奥村衣梨, 竹腰英夫, 武田秀勝 :
がん関連疲労(倦怠感)に対するエゾウコギ摂取の実⾏可能性評価試験,
第4回クロレラ・機能性植物研究集会, 2022年9月.

特許: 研究者総覧に該当データはありませんでした。
作品: 研究者総覧に該当データはありませんでした。
補助金・競争的資金: フィトケミカル含有食品エゾウコギによる、新しいNAFLD/NASH治療法の開発 (研究課題/領域番号: 22K07478 )
大腸癌のBH3プロファイリングによる抗がん剤耐性機序の解明及び新規治療法の開発 (研究課題/領域番号: 17K07200 )
NASHからの肝発癌における酸化的DNA傷害程度と修復能の検討と治療応用 (研究課題/領域番号: 15K09013 )
胃癌のBH3 プロファイリングに基づく新規抗がん剤感受性試験の開発および予後予測 (研究課題/領域番号: 26460943 )
ナローバンドUVBによる制御性T細胞の誘導を介したGVHDに対する新規治療の開発 (研究課題/領域番号: 25461429 )
慢性移植片対宿主病における調節性T細胞のBH3プロファイリング (研究課題/領域番号: 24890180 )
非アルコール性脂肪性肝炎発症における鉄代謝関連因子の分子機構解明と治療法への応用 (研究課題/領域番号: 21790676 )
ヒトhTERTストローマ細胞を用いた末梢血造血幹細胞の分裂制御機構の解析 (研究課題/領域番号: 19790672 )
TERT導入ストローマ・クローン細胞による効率的な造血幹細胞の体外増幅法の開発 (研究課題/領域番号: 17790457 )
ヘッジホッグ高発現ヒト骨髄間質細胞を用いたCD34陰性幹細胞の体外増幅法の開発 (研究課題/領域番号: 17591003 )
研究者番号（80398320）による検索

その他: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2024年11月22日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。
所属学会・所属協会: 社団法人日本内科学会
委員歴・役員歴: 研究者総覧に該当データはありませんでした。
受賞: 研究者総覧に該当データはありませんでした。
活動: 研究者総覧に該当データはありませんでした。

リサーチマップで最新データを確認するＪグローバルで最新データを確認する

2024年11月17日更新

2024年11月16日更新

Ｊグローバル

Jグローバル最終確認日: 2024/11/16 01:07
氏名（漢字）: 中村豊
氏名（フリガナ）: ナカムラユタカ
氏名（英字）: Nakamura Yutaka
所属機関: 徳島大学教授

リサーチマップ

researchmap最終確認日: 2024/11/17 03:47
氏名（漢字）: 河野豊
氏名（フリガナ）: カワノユタカ
氏名（英字）: Kawano Yutaka
プロフィール: リサーチマップAPIで取得できませんでした。
登録日時: 2015/2/19 16:27
更新日時: 2024/11/8 09:12
アバター画像URI: https://researchmap.jp/yutaou0821/avatar.jpg
ハンドル: リサーチマップAPIで取得できませんでした。
eメール: リサーチマップAPIで取得できませんでした。
eメール（その他）: リサーチマップAPIで取得できませんでした。
携帯メール: リサーチマップAPIで取得できませんでした。
性別: リサーチマップAPIで取得できませんでした。
没年月日: リサーチマップAPIで取得できませんでした。
所属ID: 0344000000
所属: 徳島大学
部署: 実践地域診療・医科学
職名: リサーチマップAPIで取得できませんでした。
学位: 医学博士
学位授与機関: 札幌医科大学
URL: リサーチマップAPIで取得できませんでした。
科研費研究者番号: リサーチマップAPIで取得できませんでした。
Google Analytics ID: リサーチマップAPIで取得できませんでした。
ORCID ID: リサーチマップAPIで取得できませんでした。
その他の所属ID: リサーチマップAPIで取得できませんでした。
その他の所属名: リサーチマップAPIで取得できませんでした。
その他の所属部署: リサーチマップAPIで取得できませんでした。
その他の所属職名: リサーチマップAPIで取得できませんでした。
最近のエントリー: リサーチマップAPIで取得できませんでした。
Read会員ID: リサーチマップAPIで取得できませんでした。
経歴: リサーチマップAPIで取得できませんでした。
受賞: リサーチマップAPIで取得できませんでした。
Misc
論文
講演・口頭発表等: リサーチマップAPIで取得できませんでした。
書籍等出版物: リサーチマップAPIで取得できませんでした。
研究キーワード
研究分野
所属学協会: リサーチマップAPIで取得できませんでした。
担当経験のある科目: リサーチマップAPIで取得できませんでした。
その他: リサーチマップAPIで取得できませんでした。
Works: リサーチマップAPIで取得できませんでした。
特許
学歴: リサーチマップAPIで取得できませんでした。
委員歴: リサーチマップAPIで取得できませんでした。
社会貢献活動: リサーチマップAPIで取得できませんでした。

ＫＡＫＥＮで最新データを確認する

2024年11月16日更新

研究者番号: 80398320

所属（現在）: 2024/4/1 : 徳島大学, 大学院医歯薬学研究部(医学域), 特任准教授

所属（過去の研究課題 情報に基づく）*注記: 2022/4/1 : 徳島大学, 大学院医歯薬学研究部(医学域), 特任准教授
2019/4/1 : 北海道医療大学, 予防医療科学センター, 准教授
2018/4/1 : 北海道医療大学, 予防医療科学センター, 講師
2017/4/1 : 札幌医科大学, 医学部, 研究員
2012/4/1 – 2017/4/1 : 札幌医科大学, 医学部, 助教
2007/4/1 – 2010/4/1 : 札幌医科大学, 医学部, 助教
2006/4/1 : 札幌医科大学, 医学部, 研究員
2005/4/1 : 札幌医科大学, 医学部, 研究生

審査区分/研究分野

研究代表者

生物系 / 医歯薬学 / 内科系臨床医学 / 消化器内科学
生物系 / 医歯薬学 / 内科系臨床医学 / 血液内科学
生物系 / 総合生物 / 腫瘍学 / 腫瘍診断学
小区分52010:内科学一般関連

研究代表者以外

生物系 / 医歯薬学 / 内科系臨床医学 / 血液内科学
生物系 / 医歯薬学 / 内科系臨床医学 / 消化器内科学

キーワード

研究代表者

ヒトストローマ / クローン / 造血幹細胞増幅 / hTERT / CD34 / ストローマ / 造血幹細胞 / 末梢血 / CD133 / 骨髄間質細胞 / NASH / 鉄代謝 / 鉄吸収試験 / Hepcidin / 除鉄療法 / CD4調節性T細胞 / 慢性移植片対宿主病 / BH3プロファイリング / 調節性T細胞 / BH3 profiling / 抗癌剤感受性 / 胃癌 / 全生存期間 / 胃がん / 大腸癌 / 大腸癌細胞株 / 5-FU耐性 / BCLXL蛋白 / 抗がん剤感受性 / 脂肪肝 / フィトケミカル / エゾウコギ / NAFLD

研究代表者以外

GVHD / NB-UVB / Treg / 臍帯血 / ストローマ / CXCR4 / CD34陰性細胞 / 造血幹細胞 / cord Blood / stromal cell / CD34 negative cell / Hematopoietic stem cell / NASH / 鉄代謝異常 / 非アルコール性脂肪肝炎 / 肝癌

研究課題研究成果共同研究者

「研究課題をさがす」で表示
テキスト（CSV）で出力

テキスト（CSV）で出力

注目研究はありません。

研究者を探す

河野 豊

Ｊグローバル

リサーチマップ

研究代表者

研究代表者以外

研究代表者

研究代表者以外

河野豊